Volume 9, Issue 2 (Vol.9 No.2 Jul 2020)                   rbmb.net 2020, 9(2): 209-215 | Back to browse issues page


XML Print


Department of Chemistry, College of Science, Al-Nahrain University, Baghdad.
Abstract:   (3122 Views)
Background: Beta thalassemia (b-thalassemia) is a type of inherited blood disorder characterized by the impaired production of beta globin chains. b-Thalassemia can be categorized into three subtypes according to symptom severity: b-thalassemia minor, b-thalassemia intermedia, and b-thalassemia major. Adipose tissue functions as an endocrine gland by synthesizing and secreting an array of bioactive peptides including leptin, adiponectin, and resistin.
Methods: We recruited 30 participants who were transfusion dependent b-thalassemia patients (major) and 30 participants who were non-transfusion dependent b-thalassemia patients (minor). The control group consisted of 20 healthy individuals. Analysis of the demographic profile, hematological profile, biochemical parameters, and serum adipokine concentrations (leptin, adiponectin and resistin) were performed for all participants.
Results: Our results showed that leptin serum levels were significantly lower in the b-thalassemia major group compared with the b-thalassemia minor group or healthy individuals, while serum levels of adiponectin were significantly higher in b-thalassemic patients compared with healthy controls. Serum levels of resistin were significantly higher in b-thalassemic patients compared with the healthy control group. A significant negative correlation was noted between adiponectin and BMI in b-thalassemic patients, whereas leptin was observed to have a significant positive correlation with BMI in the control group. Leptin was observed to have a significant negative correlation with adiponectin and ferritin in the b-thalassemia major group.
 
Conclusion: The changes we observed in adipokine levels may play a role in the development of the complications related to b-Thalassemia and disease severity.
Full-Text [PDF 196 kb]   (1527 Downloads)    
Type of Article: Case Report | Subject: Biochemistry
Received: 2020/04/29 | Accepted: 2020/05/10 | Published: 2020/10/7

References
1. Angastiniotis M, Lobitz S. Thalassemias: An overview. Int J Neonatal Screen. 2019;5(1):1-11. [DOI:10.3390/ijns5010016] [PMID] [PMCID]
2. Wafaa FA-M. The Beta-Thalassemia. Sci J Med Res. 2017;1(1):24-30. [DOI:10.37623/SJMR.2017.1105]
3. Kanavaki I, Makrythanasis P, Lazaropoulou C, Tsironi M, Kattamis A, Rombos I, et al. Soluble endothelial adhesion molecules and inflammation markers in patients with β-thalassemia intermedia. Blood Cells, Mol Dis. 2009;43(3):230-234. [DOI:10.1016/j.bcmd.2009.06.002] [PMID]
4. Jakovljević B, Paunović K, Stojanov V. Adipose tissue as an endocrine organ. Srp Arh Celok Lek. 2005;133(9-10):441-5. [DOI:10.2298/SARH05S1009M] [PMID]
5. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85-97. [DOI:10.1038/nri2921] [PMID] [PMCID]
6. Shahramian I, Akhlaghi E, Ramezani A, Rezaee A, Noori N, Sharafi E. Adipokines and the endocrine role of adipose tissues. Metabolic Control. 2015;265-282. [DOI:10.1007/164_2015_6] [PMID]
7. Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000;62:413-437. [DOI:10.1146/annurev.physiol.62.1.413] [PMID]
8. Banks WA. The many lives of leptin. Peptides. 2004;25(3):331-338. [DOI:10.1016/j.peptides.2004.02.014] [PMID]
9. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol. 2000;68(4):437-46.
10. Lee S, Kwak H-B. Role of adiponectin in metabolic and cardiovascular disease. J Exerc Rehabil. 2014;10(2):54-59. [DOI:10.12965/jer.140100] [PMID] [PMCID]
11. Abate N, S Sallam H, Rizzo M, Nikolic D, Obradovic M, Bjelogrlic P, et al. Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des. 2014;20(31):4961-9. [DOI:10.2174/1381612819666131206103102] [PMID]
12. Brown M, Wittwer C. Flow cytometry: Principles and clinical applications in hematology. Clin Chem. 2000;46(8):1221-1229. [DOI:10.1093/clinchem/46.8.1221] [PMID]
13. Choobineh H, Dehghani SJ, Alizadeh S, Ghobadi Dana V, Saiepour N, Meshkani R, et al. Evaluation of leptin levels in major beta-thalassemic patients. Iran J Ped Hematol Oncol. 2009;3(4):1-4.
14. Adel AER, Maaly M Mabrouk, MD. IMBMD. Study of Serum Leptin in Children with Beta Thalassemia: Correlation with Iron Overload. Med J Cairo Univ. 2018;86(9):3037-3045. [DOI:10.21608/mjcu.2018.59871]
15. Enli Y, Balci YI, Gönen C, Uzun E, Polat A. Adipocytokine concentrations in children with different types of beta-thalassemia. Scand J Clin Lab Invest. 2014;74(4):306-11. [DOI:10.3109/00365513.2014.883639] [PMID]
16. Deeb MM, Dawoud AA, El-Hawy MA, Wasel YFM, El Sayed AE. Study of adipocytokines (visfatin and resistin) levels in children with β-thalassemia major and intermedia. Menoufia Med J. 2019;32(3):1051-1058. [DOI:10.4103/mmj.mmj_835_17]
17. Piya MK, McTernan PG, Kumar S. Adipokine inflammation and insulin resistance: The role of glucose, lipids and endotoxin. J Endocrinol. 2013;216(1). [DOI:10.1530/JOE-12-0498] [PMID]
18. Dayer D, Salahcheh M, Jazayeri SMH, Kaydani GA, Kadkhodaei Elyaderani MK, Shaneh S. Thyroid stimulating hormone and leptin levels and severe growth retardation among Beta- thalassemic patients. Pak J Med Sci Q. 2012;28(3):421-423.
19. Youson JH, Sargent PA. Iron deposition in the integument of lampreys. Anat Rec. 1984;209(4):461-8. [DOI:10.1002/ar.1092090406] [PMID]
20. Rejholcova M, Wilhelm J, Svoboda P. Lipid peroxidation inhibits norepinephrine-stimulated lipolysis in rat adipocytes. Reduction of beta-adreno-ceptor number. Biochem Biophys Res Commun. 1988;150(2):802-810. [DOI:10.1016/0006-291X(88)90462-7]
21. Elsayh KI, Mohammed WS, Zahran AM, Saad K. Leukocytes apoptosis and adipocytokines in children with beta thalassemia major. Clin Exp Med. 2016;16(3):345-50. [DOI:10.1007/s10238-015-0361-6] [PMID]
22. Suzuki K, Ito Y, Ochiai J, Kusuhara Y, Hashimoto S, Tokudome S, et al. Relationship between obesity and serum markers of oxidative stress and inflammation in Japanese. Asian Pacific J Cancer Prev. 2003;4(3):259-66.
23. Chaliasos N, Challa A, Hatzimichael E, Koutsouka F, Bourantas DK, Vlahos AP, et al. Serum adipocytokine and vascular inflammation marker levels in beta-thalassaemia major patients. Acta Haematol. 2010;124(4):191-6. [DOI:10.1159/000320274] [PMID]
24. Ehling A, Schäffler A, Herfarth H, Tarner IH, Anders S, Distler O, et al. The potential of adiponectin in driving arthritis. J Immunol. 2006;176(7):4468-78. [DOI:10.4049/jimmunol.176.7.4468] [PMID]
25. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, et al. Adiponectin and its receptors areexpressed in bone-forming cells. Bone. 2004;35(4):842-9. [DOI:10.1016/j.bone.2004.06.008] [PMID]
26. Delaigle AM, Jonas J-C, Bauche IB, Cornu O, Brichard SM. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology. 2004;145(12):5589-97. [DOI:10.1210/en.2004-0503] [PMID]
27. Hartge MM, Unger T, Kintscher U. The endothelium and v ascular inflammation in diabetes. Diabetes Vasc Dis Res. 2007;4(2):84-8. [DOI:10.3132/dvdr.2007.025] [PMID]
28. Juan C-C, Chuang T-Y, Chang C-L, Huang S-W, Ho L-T. Endothelin-1 regulates adiponectin gene expression and secretion in 3T3-L1 adipocytes via distinct signaling pathways. Endocrinology. 2007;148(4):1835-42. [DOI:10.1210/en.2006-0654] [PMID]
29. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med. 2004;1(2):e45. [DOI:10.1371/journal.pmed.0010045] [PMID] [PMCID]
30. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway. Biochem Biophys Res Commun. 2005;334(4):1092-101. [DOI:10.1016/j.bbrc.2005.06.202] [PMID]
31. Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, Soffer D, et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol.2006;26(1):182-8. [DOI:10.1161/01.ATV.0000195790.24531.4f] [PMID]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.